Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy.
Salmon M, White HE, Zizkova H, Gottschalk A, Motlova E, Cerveira N, Colomer D, Coriu D, Franke GN, Gottardi E, Izzo B, Jurcek T, Lion T, Schäfer V, Venturi C, Vigneri P, Zawada M, Zuna J, Hovorkova L, Koblihova J, Klamova H, Markova MS, Srbova D, Benesova A, Polivkova V, Zackova D, Mayer J, Roeder I, Glauche I, Ernst T, Hochhaus A, Polakova KM, Cross NCP. Salmon M, et al. Among authors: jurcek t. Leukemia. 2022 Jul;36(7):1879-1886. doi: 10.1038/s41375-022-01612-2. Epub 2022 Jun 8. Leukemia. 2022. PMID: 35676453 Free PMC article.
Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression.
Doubek M, Palasek I, Pospisil Z, Borsky M, Klabusay M, Brychtova Y, Jurcek T, Jeziskova I, Krejci M, Dvorakova D, Mayer J. Doubek M, et al. Among authors: jurcek t. Exp Hematol. 2009 Jun;37(6):659-72. doi: 10.1016/j.exphem.2009.03.004. Exp Hematol. 2009. PMID: 19463768 Free article.
The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population.
Racil Z, Razga F, Buresova L, Jurcek T, Dvorakova D, Zackova D, Timilsina S, Cetkovsky P, Mayer J. Racil Z, et al. Among authors: jurcek t. Am J Hematol. 2010 Jul;85(7):525-8. doi: 10.1002/ajh.21722. Am J Hematol. 2010. PMID: 20575042 Free PMC article. No abstract available.
Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: can we compare real life data to the results from clinical trials?
Zackova D, Klamova H, Dusek L, Muzik J, Polakova KM, Moravcova J, Jurcek T, Dvorakova D, Racil Z, Pospisil Z, Oltova A, Michalova K, Brezinova J, Razga F, Doubek M, Cetkovsky P, Trneny M, Mayer J. Zackova D, et al. Among authors: jurcek t. Am J Hematol. 2011 Mar;86(3):318-21. doi: 10.1002/ajh.21942. Epub 2011 Feb 15. Am J Hematol. 2011. PMID: 21328429 Free article. No abstract available.
BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response.
Simara P, Peterkova M, Stejskal S, Potesilova M, Koutna I, Racil Z, Razga F, Jurcek T, Dvorakova D, Mayer J. Simara P, et al. Among authors: jurcek t. Leuk Lymphoma. 2012 Aug;53(8):1627-9. doi: 10.3109/10428194.2012.656104. Epub 2012 Mar 1. Leuk Lymphoma. 2012. PMID: 22233112 No abstract available.
Analysis of mutations in the BCR-ABL1 kinase domain, using direct sequencing: detection of the T315I mutation in bone marrow CD34+ cells of a patient with chronic myelogenous leukemia 6 months prior to its emergence in peripheral blood.
Razga F, Jurcek T, Jeziskova I, Zackova D, Dvorakova D, Borsky M, Mayer J, Racil Z. Razga F, et al. Among authors: jurcek t. Mol Diagn Ther. 2012 Jun 1;16(3):163-6. doi: 10.2165/11632420-000000000-00000. Mol Diagn Ther. 2012. PMID: 22489663
29 results